COSENTYX DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Size and Trends

Global cosentyx drug market is estimated to be valued at USD 5.32 Bn in 2024, and is expected to reach USD 8.74 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031.

To learn more about this report, request a free sample copy

The market is expected to witness growth at a steady rate during the forecast period. Rising cases of various autoimmune and inflammatory diseases such as psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and others is expected to drive the market growth. Cosentyx has demonstrated high efficacy and a well-tolerated safety profile. However, patent expiry of the drug in 2027 may impede the market's growth to some extent once cheaper biosimilars enter the market. Overall, increasing disease awareness and expanding treatment rates across developing nations will boost demand for Cosentyx during the forecast period.

Unmet Medical Need for Effective Treatment Options

The options to effectively treat psoriatic arthritis were quite limited as many patients did not respond well or had adverse reactions to conventional treatments such as methotrexate and anti-TNF drugs. Cosentyx was one of the first innovative biologic drugs that arrived in the market to address this unmet need through a novel mechanism of action. It works by selectively inhibiting the cytokine Interleukin-17A, which is a major pathogenic driver of psoriatic inflammation. In several Phase 3 clinical trials, Cosentyx demonstrated high efficacy and a fast onset of action in treating both the skin manifestations and joint symptoms associated with psoriatic arthritis. It provided long-lasting remissions and significantly improved physical function and quality of life. Moreover, Cosentyx exhibited a cleaner safety and tolerability profile relative to other drugs in its category.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

Increasing prevalence of psoriatic arthritis across the world has been a major factor contributing to growth of global cosentyx drug market. Psoriatic arthritis is a chronic inflammatory disease that results in pain, stiffness, and swelling in and around the joints. It commonly occurs in patients suffering from plaque psoriasis, a distressing and persistent form of psoriasis. According to a study published by CreakyJoints in October 2020, around 30% of people living with plaque psoriasis may eventually develop psoriatic arthritis.

To learn more about this report, request a free sample copy

One of the major challenges for the global cosentyx drug market is development of biosimilar drugs which provide cheaper treatment options for patients. As biosimilars continue to enter the market, it will put pricing pressure on Cosentyx. The patent protection for Cosentyx is expected to start expiring in 2027 which could lead to the introduction of biosimilar versions. This will further intensify competition and may affect the sales revenue of Cosentyx. Another challenge is the requirement of continuous innovation. As patients keep trying different treatment options, the drug must improve efficacy and safety profile through ongoing research.

Market Opportunities – Geographic expansion into emerging markets

Geographic expansion into emerging markets presents a great opportunity for the Cosentyx drug market. Emerging economies in Asia Pacific and Latin America are expected to witness higher rates of immune-mediated inflammatory diseases such as psoriasis and ankylosing spondylitis in the near future due to rising life expectancy, changing lifestyles and diets.

To learn more about this report, request a free sample copy

The route of administration segment includes subcutaneous injection and intravenous infusion. In terms of route of administration, subcutaneous injection segment is expected to have 67.8% of the market share in 2024, owing to its convenience and ease of administration. As Cosentyx is primarily used to treat chronic conditions like psoriasis and spondylitis, frequent dosing is required for effective management of symptoms. Subcutaneous injection allows patients to self-administer the drug at home with minimal training. This not only improves treatment adherence but also avoids the discomfort and inconvenience of visiting hospitals or clinics regularly for intravenous infusions. Furthermore, subcutaneous injections typically cause lesser pain and discomfort at the injection site compared to intramuscular injections.

Insights, By Indication: High Prevalence Drives Psoriasis Developemnt

The indication segment includes hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis and others. In terms of Indication, plaque psoriasis segment contributes the highest share of the market. Plaque psoriasis is the most common form of psoriasis affecting over 90% of people with psoriasis. It causes red, scaly patches known as plaques to appear on any part of the body but commonly affects the scalp, knees, elbows, trunk and limbs. Plaque psoriasis can profoundly impair quality of life through physical symptoms of itching, stinging and pain as well as psychological issues related to its appearance. The disfiguring nature of psoriatic plaques and high prevalence of the condition can boost demand for effective targeted treatments like Cosentyx.  

Insights, By Distribution Channel: Convenience Drives Hospital Pharmacies Growth

The distribution channel segment includes hospital pharmacies, online pharmacies, and retail pharmacies. In terms of distribution channel, hospital pharmacies segment is anticipated to have 41.9% of the market share in 2024. As a biologic injectable for chronic diseases, Cosentyx requires proper storage, handling and administration by trained medical professionals. Hospital pharmacies have extensive experience and infrastructure for managing specialty drugs under strict protocols. These also have a network of affiliated clinics and centres that enables wider access for patients in remote areas. This clinical expertise and geographic coverage make hospital pharmacies the preferred channel for distribution of Cosentyx injections.

Regional Insights

To learn more about this report, request a free sample copy

North America region is anticipated to dominate the market with 45.7% of the market share in 2024. With a large population suffering from autoimmune disorders including psoriasis and arthritis, Cosentyx has a huge potential patient pool. Most private and public health plans also provide decent coverage for expensive biologic drugs like Cosentyx, thus, ensuring affordability and access for patients. Promising clinical research trials conducted in the U.S. also influence prescribing habits of doctors. With several manufacturing sites located within the country, logistical and supply chain management for Cosentyx is well-streamlined in the region.

The Asia Pacific region is fast becoming an important emerging market for Cosentyx. This can be attributed to rising disease prevalence in developing economies like China and India, owing to changing lifestyles. These nations also have a very large patient pool suffering from various autoimmune conditions. Rising incomes has made expensive biologic treatments potentially viable options for Asian patients as well. However, lack of awareness still remains a critical challenge to be addressed by all stakeholders in the APAC Cosentyx market.

Market Report Scope

Key Developments

• In October 2023, Novartis AG, a global leader in immuno-dermatology and rheumatology, announced that the U.S. Food and Drug Administration (FDA) had approved Cosentyx (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only U.S. FDA-approved completely human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine thought to be involved in the inflammation of HS.
• In October 2023, Novartis AG, a global leader in immuno-dermatology and rheumatology, announced that the U.S. FDA had approved an intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA)
• In December 2021, Novartis AG, a global leader in immuno-dermatology and rheumatology, announced that the U.S. FDA had approved Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in patients four years and older, and active psoriatic arthritis (PsA) in patients two years or older

*Definition: Cosentyx is a prescription medication that is used for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by inhibiting an immune system protein called interleukin-17A (IL-17A), which plays a central role in the inflammation associated with these conditions. Cosentyx is administered through subcutaneous injection. It has been shown to effectively reduce symptoms such as skin lesions, joint pain and swelling for patients

Market Segmentation

• Route of Administration Insights (Revenue, USD BN, 2019 - 2031)
  • Subcutaneous injection
  • Intravenous infusion
•  Indication Insights (Revenue, USD BN, 2019 - 2031)
  • Hidradenitis suppurativa
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Plaque Psoriasis
  • Others
•  Distribution Channel Insights (Revenue, USD BN, 2019 - 2031)
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
• Regional Insights (Revenue, USD BN, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of the Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Novartis AG